Together, these findings provide a new paradigm where high-risk MM/pPCL is characterized by high levels of Notch signaling that can partially compensate for lower IL-6 in the extramedullary microenvironment, possibly by activating IL-6 autonomous production. Here, IL6 is linked to Miyoshi myopathy.